Atrial protective effects of n-3 polyunsaturated fatty acids: A long-term study in ovine chronic heart failure

Dennis H. Lau, Peter J. Psaltis, Angelo Carbone, Darren J. Kelly, Lorraine MacKenzie, Michael Worthington, Robert G. Metcalf, Pawel Kuklik, Adam J. Nelson, Yuan Zhang, Christopher X. Wong, Anthony G. Brooks, David A. Saint, Michael J. James, James Edwards, Glenn D. Young, Stephen G. Worthley, Prashanthan Sanders

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: It has been suggested that omega-3 polyunsaturated fatty acids (n-3 PUFAs) may prevent the development of atrial fibrillation (AF). Objective: The purpose of this study was to evaluate the impact of these agents on development of the AF substrate in heart failure (HF). Methods: In this study, HF was induced by intracoronary doxorubicin infusions. Twenty-one sheep [7 with n-3 PUFAs treated HF (HF-PUFA), 7 with olive oiltreated HF controls (HF-CTL), 7 controls (CTL)] were studied. Open chest electrophysiologic study was performed with assessment of biatrial effective refractory period (ERP) and conduction. Cardiac function was monitored by magnetic resonance imaging. Atrial n-3 PUFAs levels were quantified using chromatography. Structural analysis was also performed. Results: Atrial n-3 PUFAs levels were twofold to threefold higher in the HF-PUFA group. n-3 PUFAs prevented the development of HF-related left atrial enlargement (P = .001) but not left ventricular/atrial dysfunction. Atrial ERP was significantly lower in the HF-PUFA group (P <.001), but ERP heterogeneity was unchanged. In addition, n-3 PUFAs suppressed atrial conduction abnormalities seen in HF of prolonged P-wave duration (P = .01) and slowed (P <.001) and heterogeneous (P <.05) conduction. The duration of induced AF episodes in HF-PUFA was shorter (P = .02), although AF inducibility was unaltered (P = NS). A 20% reduction of atrial interstitial fibrosis was seen in the HF-PUFA group (P <.05). Conclusion: In this ovine HF study, chronic n-3 PUFAs use protected against adverse atrial remodeling by preventing atrial enlargement, fibrosis, and conduction abnormalities leading to shorter AF episodes despite lower ERP. Crown

LanguageEnglish
Pages575-582
Number of pages8
JournalHeart Rhythm
Volume8
Issue number4
DOIs
Publication statusPublished - 1 Apr 2011

Keywords

  • Atrial fibrillation
  • Congestive heart failure
  • Omega-3 polyunsaturated fatty acid
  • Remodeling

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Lau, Dennis H. ; Psaltis, Peter J. ; Carbone, Angelo ; Kelly, Darren J. ; MacKenzie, Lorraine ; Worthington, Michael ; Metcalf, Robert G. ; Kuklik, Pawel ; Nelson, Adam J. ; Zhang, Yuan ; Wong, Christopher X. ; Brooks, Anthony G. ; Saint, David A. ; James, Michael J. ; Edwards, James ; Young, Glenn D. ; Worthley, Stephen G. ; Sanders, Prashanthan. / Atrial protective effects of n-3 polyunsaturated fatty acids : A long-term study in ovine chronic heart failure. In: Heart Rhythm. 2011 ; Vol. 8, No. 4. pp. 575-582.
@article{8426c51d623d4c40a8ed83652160db71,
title = "Atrial protective effects of n-3 polyunsaturated fatty acids: A long-term study in ovine chronic heart failure",
abstract = "Background: It has been suggested that omega-3 polyunsaturated fatty acids (n-3 PUFAs) may prevent the development of atrial fibrillation (AF). Objective: The purpose of this study was to evaluate the impact of these agents on development of the AF substrate in heart failure (HF). Methods: In this study, HF was induced by intracoronary doxorubicin infusions. Twenty-one sheep [7 with n-3 PUFAs treated HF (HF-PUFA), 7 with olive oiltreated HF controls (HF-CTL), 7 controls (CTL)] were studied. Open chest electrophysiologic study was performed with assessment of biatrial effective refractory period (ERP) and conduction. Cardiac function was monitored by magnetic resonance imaging. Atrial n-3 PUFAs levels were quantified using chromatography. Structural analysis was also performed. Results: Atrial n-3 PUFAs levels were twofold to threefold higher in the HF-PUFA group. n-3 PUFAs prevented the development of HF-related left atrial enlargement (P = .001) but not left ventricular/atrial dysfunction. Atrial ERP was significantly lower in the HF-PUFA group (P <.001), but ERP heterogeneity was unchanged. In addition, n-3 PUFAs suppressed atrial conduction abnormalities seen in HF of prolonged P-wave duration (P = .01) and slowed (P <.001) and heterogeneous (P <.05) conduction. The duration of induced AF episodes in HF-PUFA was shorter (P = .02), although AF inducibility was unaltered (P = NS). A 20{\%} reduction of atrial interstitial fibrosis was seen in the HF-PUFA group (P <.05). Conclusion: In this ovine HF study, chronic n-3 PUFAs use protected against adverse atrial remodeling by preventing atrial enlargement, fibrosis, and conduction abnormalities leading to shorter AF episodes despite lower ERP. Crown",
keywords = "Atrial fibrillation, Congestive heart failure, Omega-3 polyunsaturated fatty acid, Remodeling",
author = "Lau, {Dennis H.} and Psaltis, {Peter J.} and Angelo Carbone and Kelly, {Darren J.} and Lorraine MacKenzie and Michael Worthington and Metcalf, {Robert G.} and Pawel Kuklik and Nelson, {Adam J.} and Yuan Zhang and Wong, {Christopher X.} and Brooks, {Anthony G.} and Saint, {David A.} and James, {Michael J.} and James Edwards and Young, {Glenn D.} and Worthley, {Stephen G.} and Prashanthan Sanders",
year = "2011",
month = "4",
day = "1",
doi = "10.1016/j.hrthm.2010.12.009",
language = "English",
volume = "8",
pages = "575--582",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "4",

}

Lau, DH, Psaltis, PJ, Carbone, A, Kelly, DJ, MacKenzie, L, Worthington, M, Metcalf, RG, Kuklik, P, Nelson, AJ, Zhang, Y, Wong, CX, Brooks, AG, Saint, DA, James, MJ, Edwards, J, Young, GD, Worthley, SG & Sanders, P 2011, 'Atrial protective effects of n-3 polyunsaturated fatty acids: A long-term study in ovine chronic heart failure', Heart Rhythm, vol. 8, no. 4, pp. 575-582. https://doi.org/10.1016/j.hrthm.2010.12.009

Atrial protective effects of n-3 polyunsaturated fatty acids : A long-term study in ovine chronic heart failure. / Lau, Dennis H.; Psaltis, Peter J.; Carbone, Angelo; Kelly, Darren J.; MacKenzie, Lorraine; Worthington, Michael; Metcalf, Robert G.; Kuklik, Pawel; Nelson, Adam J.; Zhang, Yuan; Wong, Christopher X.; Brooks, Anthony G.; Saint, David A.; James, Michael J.; Edwards, James; Young, Glenn D.; Worthley, Stephen G.; Sanders, Prashanthan.

In: Heart Rhythm, Vol. 8, No. 4, 01.04.2011, p. 575-582.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Atrial protective effects of n-3 polyunsaturated fatty acids

T2 - Heart Rhythm

AU - Lau, Dennis H.

AU - Psaltis, Peter J.

AU - Carbone, Angelo

AU - Kelly, Darren J.

AU - MacKenzie, Lorraine

AU - Worthington, Michael

AU - Metcalf, Robert G.

AU - Kuklik, Pawel

AU - Nelson, Adam J.

AU - Zhang, Yuan

AU - Wong, Christopher X.

AU - Brooks, Anthony G.

AU - Saint, David A.

AU - James, Michael J.

AU - Edwards, James

AU - Young, Glenn D.

AU - Worthley, Stephen G.

AU - Sanders, Prashanthan

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Background: It has been suggested that omega-3 polyunsaturated fatty acids (n-3 PUFAs) may prevent the development of atrial fibrillation (AF). Objective: The purpose of this study was to evaluate the impact of these agents on development of the AF substrate in heart failure (HF). Methods: In this study, HF was induced by intracoronary doxorubicin infusions. Twenty-one sheep [7 with n-3 PUFAs treated HF (HF-PUFA), 7 with olive oiltreated HF controls (HF-CTL), 7 controls (CTL)] were studied. Open chest electrophysiologic study was performed with assessment of biatrial effective refractory period (ERP) and conduction. Cardiac function was monitored by magnetic resonance imaging. Atrial n-3 PUFAs levels were quantified using chromatography. Structural analysis was also performed. Results: Atrial n-3 PUFAs levels were twofold to threefold higher in the HF-PUFA group. n-3 PUFAs prevented the development of HF-related left atrial enlargement (P = .001) but not left ventricular/atrial dysfunction. Atrial ERP was significantly lower in the HF-PUFA group (P <.001), but ERP heterogeneity was unchanged. In addition, n-3 PUFAs suppressed atrial conduction abnormalities seen in HF of prolonged P-wave duration (P = .01) and slowed (P <.001) and heterogeneous (P <.05) conduction. The duration of induced AF episodes in HF-PUFA was shorter (P = .02), although AF inducibility was unaltered (P = NS). A 20% reduction of atrial interstitial fibrosis was seen in the HF-PUFA group (P <.05). Conclusion: In this ovine HF study, chronic n-3 PUFAs use protected against adverse atrial remodeling by preventing atrial enlargement, fibrosis, and conduction abnormalities leading to shorter AF episodes despite lower ERP. Crown

AB - Background: It has been suggested that omega-3 polyunsaturated fatty acids (n-3 PUFAs) may prevent the development of atrial fibrillation (AF). Objective: The purpose of this study was to evaluate the impact of these agents on development of the AF substrate in heart failure (HF). Methods: In this study, HF was induced by intracoronary doxorubicin infusions. Twenty-one sheep [7 with n-3 PUFAs treated HF (HF-PUFA), 7 with olive oiltreated HF controls (HF-CTL), 7 controls (CTL)] were studied. Open chest electrophysiologic study was performed with assessment of biatrial effective refractory period (ERP) and conduction. Cardiac function was monitored by magnetic resonance imaging. Atrial n-3 PUFAs levels were quantified using chromatography. Structural analysis was also performed. Results: Atrial n-3 PUFAs levels were twofold to threefold higher in the HF-PUFA group. n-3 PUFAs prevented the development of HF-related left atrial enlargement (P = .001) but not left ventricular/atrial dysfunction. Atrial ERP was significantly lower in the HF-PUFA group (P <.001), but ERP heterogeneity was unchanged. In addition, n-3 PUFAs suppressed atrial conduction abnormalities seen in HF of prolonged P-wave duration (P = .01) and slowed (P <.001) and heterogeneous (P <.05) conduction. The duration of induced AF episodes in HF-PUFA was shorter (P = .02), although AF inducibility was unaltered (P = NS). A 20% reduction of atrial interstitial fibrosis was seen in the HF-PUFA group (P <.05). Conclusion: In this ovine HF study, chronic n-3 PUFAs use protected against adverse atrial remodeling by preventing atrial enlargement, fibrosis, and conduction abnormalities leading to shorter AF episodes despite lower ERP. Crown

KW - Atrial fibrillation

KW - Congestive heart failure

KW - Omega-3 polyunsaturated fatty acid

KW - Remodeling

UR - http://www.scopus.com/inward/record.url?scp=79953246427&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2010.12.009

DO - 10.1016/j.hrthm.2010.12.009

M3 - Article

VL - 8

SP - 575

EP - 582

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 4

ER -